新的维生素 D 及其类似物在肾病中的临床试验。
New clinical trials with vitamin D and analogs in renal disease.
出版信息
Kidney Int. 2011 Oct;80(8):793-6. doi: 10.1038/ki.2011.260. Epub 2011 Aug 10.
Abstract
Two new clinical trials highlight refinements in the use of vitamin D and its analogs in the treatment of secondary hyperparathyroidism in end-stage renal disease (ESRD), and the treatment of proteinuria in diabetics. In patients with ESRD, alfacalcidol is as effective as paricalcitol in suppressing parathyroid hormone; the occurrence of hypercalcemia and hyperphosphatemia is infrequent and similar with the two analogs. Oral cholecalciferol reduces albuminuria and urinary transforming growth factor-β1 in patients with type 2 diabetes mellitus and proteinuria.
摘要
两项新临床试验突出了维生素 D 及其类似物在治疗终末期肾病（ESRD）继发性甲状旁腺功能亢进症和糖尿病患者蛋白尿方面的应用改进。在 ESRD 患者中，阿尔法骨化醇在抑制甲状旁腺激素方面与帕立骨化醇同样有效；两种类似物发生高钙血症和高磷血症的情况并不常见且相似。口服胆钙化醇可减少 2 型糖尿病和蛋白尿患者的蛋白尿和尿转化生长因子-β1。
相似文献
1
New clinical trials with vitamin D and analogs in renal disease.新的维生素 D 及其类似物在肾病中的临床试验。
Kidney Int. 2011 Oct;80(8):793-6. doi: 10.1038/ki.2011.260. Epub 2011 Aug 10.
2
Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.口服胆钙化醇可降低已接受肾素-血管紧张素-醛固酮系统抑制治疗的 2 型糖尿病肾病患者的蛋白尿和尿转化生长因子-β1。
Kidney Int. 2011 Oct;80(8):851-60. doi: 10.1038/ki.2011.224. Epub 2011 Aug 10.
3
Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol.血液透析患者继发性甲状旁腺功能亢进的治疗：一项比较帕立骨化醇和阿法骨化醇的随机临床试验。
BMC Nephrol. 2009 Sep 24;10:28. doi: 10.1186/1471-2369-10-28.
4
A randomised clinical study of alfacalcidol and paricalcitol.阿法骨化醇与帕立骨化醇的一项随机临床研究。
Dan Med J. 2012 Feb;59(2):B4400.
5
No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial.阿法骨化醇与帕立骨化醇治疗血液透析患者继发性甲状旁腺功能亢进症的疗效比较：一项随机交叉试验。
Kidney Int. 2011 Oct;80(8):841-50. doi: 10.1038/ki.2011.226. Epub 2011 Aug 10.
6
7
Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.帕立骨化醇、骨化三醇和阿法骨化醇治疗血液透析期间继发性甲状旁腺功能亢进的卫生经济学比较
Clin Drug Investig. 2007;27(12):865-6. doi: 10.2165/00044011-200727120-00010.
8
Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol.使用阿法骨化醇或帕立骨化醇治疗继发性甲状旁腺功能亢进期间成纤维细胞生长因子23的变化。
Nephrol Dial Transplant. 2012 Jun;27(6):2263-9. doi: 10.1093/ndt/gfr668. Epub 2011 Dec 1.
9
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.选择性维生素 D 受体激活剂帕立骨化醇降低 2 型糖尿病患者蛋白尿（VITAL 研究）：一项随机对照试验。
Lancet. 2010 Nov 6;376(9752):1543-51. doi: 10.1016/S0140-6736(10)61032-X.
10
Health-economic comparison of paricalcitol, calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism during haemodialysis.帕立骨化醇、骨化三醇和阿法骨化醇治疗血液透析期间继发性甲状旁腺功能亢进的卫生经济学比较
Clin Drug Investig. 2006;26(11):629-38. doi: 10.2165/00044011-200626110-00002.
引用本文的文献
1
The study of serum vitamin d and insulin resistance in chinese populations with normal glucose tolerance.中国糖耐量正常人群血清维生素 D 与胰岛素抵抗相关性研究。
Int J Endocrinol. 2014;2014:870235. doi: 10.1155/2014/870235. Epub 2014 Sep 1.
2
Comparison of oral and intravenous alfacalcidol in chronic hemodialysis patients.口服和静脉用阿法骨化醇在慢性血液透析患者中的比较。
BMC Nephrol. 2014 Feb 4;15:27. doi: 10.1186/1471-2369-15-27.
3
Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options.慢性肾脏病：对发病机制和治疗选择的新认识。
Pediatr Nephrol. 2014 May;29(5):779-92. doi: 10.1007/s00467-013-2436-5. Epub 2013 Mar 8.
本文引用的文献
1
Short-term effects of vitamin D receptor activation on serum creatinine, creatinine generation, and glomerular filtration.维生素 D 受体激活对血清肌酐、肌酐生成和肾小球滤过的短期影响。
Kidney Int. 2011 Nov;80(10):1016-7. doi: 10.1038/ki.2011.265.
2
Oral cholecalciferol decreases albuminuria and urinary TGF-β1 in patients with type 2 diabetic nephropathy on established renin-angiotensin-aldosterone system inhibition.口服胆钙化醇可降低已接受肾素-血管紧张素-醛固酮系统抑制治疗的 2 型糖尿病肾病患者的蛋白尿和尿转化生长因子-β1。
Kidney Int. 2011 Oct;80(8):851-60. doi: 10.1038/ki.2011.224. Epub 2011 Aug 10.
3
No difference between alfacalcidol and paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized crossover trial.阿法骨化醇与帕立骨化醇治疗血液透析患者继发性甲状旁腺功能亢进症的疗效比较：一项随机交叉试验。
Kidney Int. 2011 Oct;80(8):841-50. doi: 10.1038/ki.2011.226. Epub 2011 Aug 10.
4
The regulation of parathyroid hormone secretion and synthesis.甲状旁腺激素分泌与合成的调节。
J Am Soc Nephrol. 2011 Feb;22(2):216-24. doi: 10.1681/ASN.2010020186. Epub 2010 Dec 16.
5
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.选择性维生素 D 受体激活剂帕立骨化醇降低 2 型糖尿病患者蛋白尿（VITAL 研究）：一项随机对照试验。
Lancet. 2010 Nov 6;376(9752):1543-51. doi: 10.1016/S0140-6736(10)61032-X.
6
KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD).KDIGO 美国评论：2009 年 KDIGO 慢性肾脏病-矿物质和骨异常（CKD-MBD）诊断、评估和治疗临床实践指南。
Am J Kidney Dis. 2010 May;55(5):773-99. doi: 10.1053/j.ajkd.2010.02.340. Epub 2010 Apr 3.
7
Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial.口服骨化三醇治疗免疫球蛋白A肾病持续性蛋白尿：一项非对照试验
Am J Kidney Dis. 2008 May;51(5):724-31. doi: 10.1053/j.ajkd.2007.12.038. Epub 2008 Apr 3.
8
Differential effects of vitamin D receptor activators on vascular calcification in uremic rats.维生素D受体激活剂对尿毒症大鼠血管钙化的不同作用
Kidney Int. 2007 Sep;72(6):709-15. doi: 10.1038/sj.ki.5002406. Epub 2007 Jun 27.
9
25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III).第三次全国健康与营养检查调查（NHANES III）中的25-羟基维生素D水平与蛋白尿
Am J Kidney Dis. 2007 Jul;50(1):69-77. doi: 10.1053/j.ajkd.2007.04.015.
10
Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.维持性血液透析中的矿物质代谢、死亡率和发病率
J Am Soc Nephrol. 2004 Aug;15(8):2208-18. doi: 10.1097/01.ASN.0000133041.27682.A2.
Zotero 插件